Generics Bulletin is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK expects to save 75% from adalimumab rivals

Executive Summary

Savings of around 75% on the cost of adalimumab are expected by the UK’s National Health Service (NHS) “after negotiating deals with five manufacturers on low-cost versions of the health service’s most costly drug”. The NHS said it had “moved swiftly to drive strong competition between biosimilar manufacturers and the manufacturer of the originator brand, resulting in huge cost discounts”.

Advertisement

Related Content

Fresenius Nod In EU Adds To Crowded Adalimumab Market
German Adalimumab Biosimilars Near A Third
Advertisement
UsernamePublicRestriction

Register

GB001506

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel